By Patrick Wingrove
(Reuters) – Novavax Inc cut about $50 million in costs in the first quarter of 2023 and plans to slash more, Chief Executive John Jacobs said in an interview on Wednesday.
Jacobs also said the company is in regular talks with the U.S. Food and Drug Administration over the potential design of its 2023 COVID-19 booster shot, and believes Novavax will have a new shot ready in time for the fall.
(Reporting by Patrick Wingrove; Editing by Bill Berkrot)
